Payment overview · 2025
General Payments
$100.67
6 reported records · 5 companies
Healthcare provider profile · identity verified
Alexander Campolo, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEWARK, OH · NPI 1306230255
Verified facts
What the public records show
CMS Open Payments records show Alexander Campolo, D.O. received $100.67 in general payments during 2025 across 6 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.25 | 33.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.07 | 20.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.42 | 16.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.62 | 15.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.31 | 14.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $100.67 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $32.46 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 204 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1031 | 338 |
| Lisinopril | Lisinopril | 605 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 195 |
| Losartan Potassium | Losartan Potassium | 523 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 501 | 144 |
| Omeprazole | Omeprazole | 457 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 321 | 119 |
| Metformin Hcl | Metformin Hcl | 288 | 102 |
| Gabapentin | Gabapentin | 282 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 248 | 81 |
| Glimepiride | Glimepiride | 238 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 92 |
| Simvastatin | Simvastatin | 228 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 72 |
| Furosemide | Furosemide | 214 | 85 |
| Eliquis | Apixaban | 204 | 56 |
| Trazodone Hcl | Trazodone Hcl | 190 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 171 | 59 |
| Potassium Chloride | Potassium Chloride | 170 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 52 |
| Carvedilol | Carvedilol | 155 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 40 |
| Alendronate Sodium | Alendronate Sodium | 143 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 40 |
| Sertraline Hcl | Sertraline Hcl | 126 | 39 |
| Ozempic | Semaglutide | 122 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 37 |
| Montelukast Sodium | Montelukast Sodium | 111 | 33 |
| Allopurinol | Allopurinol | 110 | 39 |
| Alprazolam | Alprazolam | 100 | 27 |
| Jardiance | Empagliflozin | 100 | 32 |
| Tramadol Hcl | Tramadol Hcl | 100 | 26 |
| Celecoxib | Celecoxib | 99 | 29 |
| Meloxicam | Meloxicam | 99 | 32 |
| Buspirone Hcl | Buspirone Hcl | 97 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 20 |
| Fenofibrate | Fenofibrate | 84 | 27 |
| Synthroid | Levothyroxine Sodium | 79 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 14 |
| Januvia | Sitagliptin Phosphate | 74 | 22 |
| Spironolactone | Spironolactone | 70 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 16 |
| Prednisone | Prednisone | 66 | 50 |
| Warfarin Sodium | Warfarin Sodium | 66 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 17 |
| Ezetimibe | Ezetimibe | 64 | 21 |
| Pregabalin | Pregabalin | 63 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 60 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 19 |
| Trulicity | Dulaglutide | 58 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 12 |
| Famotidine | Famotidine | 57 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 56 | 13 |
| Atenolol | Atenolol | 55 | 17 |
| Metformin Hcl Er | Metformin Hcl | 55 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 13 |
| Bupropion Xl | Bupropion Hcl | 53 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 20 |
| Valsartan | Valsartan | 53 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 18 |
| Finasteride | Finasteride | 50 | 15 |
| Methylprednisolone | Methylprednisolone | 50 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 13 |
| Lorazepam | Lorazepam | 46 | 16 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Baclofen | Baclofen | 42 | 15 |
| Synjardy | Empagliflozin/Metformin Hcl | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 12 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 14 |
| Mounjaro | Tirzepatide | 37 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 31 |
| Glipizide | Glipizide | 36 | 11 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 12 |
| Azithromycin | Azithromycin | 34 | 29 |
| Lovastatin | Lovastatin | 34 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 25 |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 15 | suppressed |
| Topiramate Er | Topiramate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 12 |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $100.67 · 6 records | E.R. Squibb & Sons, L.L.C. | Auvelity, BOTOX, CAMZYOS, Dexcom G6 Transmitter, ELIQUIS, NURTEC ODT | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error